The board of directors of Ind Swift Laboratories (Q, N,C,F)* at its meeting held on Aug. 29, 2008, has allotted 322,000 equity shares of Rs 10 each at a premium of Rs 60 a share to promoter group upon the conversion of 322,000 zero coupon optionally convertible warrants.

Ind Swift Laboratories manufactures a wide range of solid, liquid, semi liquid forms, capsule, tablets, dry/liquid injectable eye/ear drops, oral solution, and creams/gels.

The company`s products include Clarithromycin, Fexofenadine, Clarie granules, Pentazocine, Roxithromycin, Clopidogrel, Azithromycin, and Atorvastatin. Its products are used in the macrolide antibiotic, antiallergy, cardiovascular, diabetology, and antiulcerant therapeutic sector.

Shares of the company declined Rs 0.85, or 1.8%, to trade at Rs 46.25. The total volume of shares traded was 2,061 at the BSE (11.34 a.m., Monday).